Role of C5b-9 and RGC-32 in Cancer

Sonia I. Vlaicu 1,2, Alexandru Tatomir 2, Violeta Rus 3 and Horea Rus 2*

1 Department of Internal Medicine, “Iuliu Hatieganu” University of Medicine and Pharmacy, Cluj-Napoca, Romania, 2 Department of Neurology, School of Medicine, University of Maryland, Baltimore, MD, United States, 3 Division of Rheumatology and Immunology, Department of Medicine, School of Medicine, University of Maryland, Baltimore, MD, United States

The complement system represents an effective arsenal of innate immunity as well as an interface between innate and adaptive immunity. Activation of the complement system culminates with the assembly of the C5b-9 terminal complement complex on cell membranes, inducing target cell lysis. Translation of this sequence of events into a malignant setting has traditionally afforded C5b-9 a strict antitumoral role, in synergy with antibody-dependent tumor cytolysis. However, in recent decades, a plethora of evidence has revised this view, highlighting the tumor-promoting properties of C5b-9. Sublytic C5b-9 induces cell cycle progression by activating signal transduction pathways (e.g., Gi protein/ phosphatidylinositol 3-kinase (PI3K)/Akt kinase and Ras/Raf1/ERK1) and modulating the activation of cancer-related transcription factors, while shielding malignant cells from apoptosis. C5b-9 also induces Response Gene to Complement (RGC)-32, a gene that contributes to cell cycle regulation by activating the Akt and CDC2 kinases. RGC-32 is expressed by tumor cells and plays a dual role in cancer, functioning as either a tumor promoter by endorsing malignancy initiation, progression, invasion, metastasis, and angiogenesis, or as a tumor suppressor. In this review, we present recent data describing the versatile, multifaceted roles of C5b-9 and its effector, RGC-32, in cancer.

Keywords: C5b-9, cancer, RGC-32, cell proliferation, apoptosis

INTRODUCTION

Carcinogenesis in human somatic cells involves a series of genetic and epigenetic alterations that culminate in the generation of a malignant tissue fully prepared to elude most anticancer defense strategies. To date, there are seven key alterations in cancerous cells: self-sufficiency in growth signals; insensitivity to growth suppressors; evasion of apoptosis, enabling replicative immortality; sustained angiogenesis; tissue invasion (metastasis) (1) and the presence of cancer-related inflammation (CRI) (2). Essential orchestrators of CRI are the tumor-associated inflammatory cells (macrophages, fibroblasts, T cells and myeloid-derived suppressor cells) and their secreted chemokines and cytokines, along with complement activation within the tumor microenvironment (2, 3).

The complement system represents an effective arsenal of innate immunity as well as an interface between innate and adaptive immunity. An ancestral instrument in fighting invasive pathogens and efficient clearance of debris, the complement system can be activated by the classical, alternative, or lectin pathway, all of which unite at the level of C3 activation. All three pathways lead to the membrane attack complex formation and to cell lysis. Activation of the terminal complement proteins C5 to C9 generates membrane-inserted complexes C5b-7, C5b-8, and finally C5b-9, the so-called membrane attack complex (MAC) (4, 5).
Evidence supporting complement activation, in association with C5b-9 deposits during the antitumoral response exists for a variety of human malignancies (6). Niculescu et al. provided the first immunohistochemical support for the presence of C5b-9 deposits (along with IgG, C3 and C4 deposits) in a human cancerous tissue, namely breast carcinoma (3). Thereafter, numerous studies demonstrated C5b-9 deposition indicating complement activation in human thyroid (7), ovarian (8), endometrial (6), gastric (6–10), liver (6), colon, renal, and lung carcinomas (11), as well as in human osteosarcoma (12), medulloblastoma (6), glioma (6, 13), and gastrointestinal stromal tumor (6) tissues. High levels of soluble C5b-9 were also detected in the ascitic fluid of ovarian cancer (14). Elevated circulating C9 protein levels have been reported in the serum or plasma of colon (15) and gastric (16) adenocarcinoma, oral squamous cell carcinoma (17) and squamous cell lung cancer (18) patients.

C5b-9 has been shown to possess antitumoral properties, acting in synergy with monoclonal antibody (mAb)-based immunotherapies, many of which use complement activation and C5b-9 as an effector to kill tumor cells (19, 20). In this context, the mAb triggers C5b-9 assembly on cells leading to tumor destruction. Nevertheless, in recent decades, a plethora of evidence has brought about a conceptual switch in this paradigm (21) and exposed the tumor-promoter properties of C5b-9.

Here, we summarize the available data concerning the complex and versatile role of C5b-9, and that of its pivotal effector RGC-32, in cancer.

**EFFECTS OF LYTIC C5b-9 ON TUMOR CELLS**

Successful achievement of cell lysis during complement-dependent cytotoxicity (CDC) requires the formation of multiple C5b-9 complexes on the cell surface (22). Once malignant Ehrlich ascites cells already bearing C5b-8 complexes are exposed to C9, a rapid and extensive ATP depletion, coupled with leakage of the adenine nucleotides ATP, ADP, and AMP, precedes cell death. Other prelytic events include the loss of mitochondrial membrane potential with consequent defective ATP synthesis and a vigorous Ca\(^{2+}\) influx, which initiate necrotic cell death (23).

The morphologic and biochemical changes induced by lytic MAC attack do share some features with those seen in apoptosis (necroelar changes), although most features correspond more closely to necrotic changes (loss of volume control and defective mitochondria) (5, 24). The main biochemical changes include Bid cleavage, caspase activation, and activation of extracellular DNases (25–27). The impact of lytic C5b-9 on the malignant signaling pathways is multifaceted, since CDC has been documented to use several necrotic cell death pathways involving the receptor-interacting protein kinase 1 (RIPK1), receptor-interacting protein kinase 3 (RIPK3) and mixed-lineage kinase domain-like protein (MLKL) (28), in concert with the effectors JNK and Bid. The RIPK1/RIPK3/MLKL pathway closely resembles TNF-alpha-induced necroptosis (28).

Tumor cells have developed complement resistance through C5b-9 removal (29), expression of membrane complement-regulatory proteins (mCRPs) and other cell surface-protective molecules, and secretion of soluble complement inhibitors (30, 31). The ability of a cell to survive an initial complement-mediated membrane attack affords its resistance against future attacks (32).

The use of mAb-based immunotherapies that stimulate the destruction of tumor cells by CDC has received a lot of interest (19). The quest for optimal efficacy in CDC has incited many research teams. For instance, Diebold et al. have shown that IgG hexamerization after antigen binding leads to more effective complement activation and fixation, and thus a more potent CDC (33). Narrow C5b-8 pores formed without C9 are sufficient for CDC due to efficient antibody-mediated hexamer formation (34). By neutralizing mCRP expression on leukemia cells, Mamidi et al. were the first to achieve both enhanced CDC and improved complement-dependent cellular cytotoxicity by monocyte-derived macrophages and macrophages induced by two anti-CD20 antibodies (rituximab and ofatumumab) and one anti-CD52 antibody (alemuzumab) (35). Of late, the miR-200b, miR-200c, and miR-217 microRNAs have been recognized as potential regulators of mortalin as well as CD46 and CD55 expression in leukemia/lymphoma and have been observed to coordinate the quantity of C5b-9 deposited on target cells (36).

**SUBLYTIC C5b-9 INDUCES TUMOR CELL PROLIFERATION AND TRANSCRIPTIONAL ACTIVATION IN MALIGNANT CELLS**

Sublytic levels of C5b-9 assembly in the membrane of malignant cells generate several different biological responses: activation of signal transduction pathways, proliferation, and modulation of apoptosis (5, 37) (Figure 1).

One of the first investigations of C5b-9 looked at the generation of signal messengers in Ehrlich carcinoma cells by the sublytic terminal complement complexes (TCC) C5b-9, C5b-8, and C5b-7 and identified the signal messengers involved in eliminating TCC from the cell surface (44). Exposure of Ehrlich carcinoma cells to C5b-9 caused an increase in cytosolic Ca\(^{2+}\). In addition, sublytic C5b-9 and C5b-8 substantially increased PKC activity, and C5b-8 and C5b-7 induced an increase in CAMP (44). In another report, sublytic C5b-9 assembly in lymphoblastoid human B cells stimulated the production of diacylglycerol (DAG) and ceramide (mediators of inflammation and tissue repair), along with PKC activation (45). Rapid elimination of TCC...
Sublytic C5b-9 promotes tumor growth and survival by activating several signaling pathways. The assembly of C5b-9 complexes in the cellular membrane activates the heterotrimeric G proteins of the Gi subtype (38). The β-γ complex is thought to activate several intracellular signaling cascades, including: a) phosphatidylinositol 3 kinase (PI3K)-Akt signaling pathway. Activated Akt phosphorylates and inactivates the pro-apoptotic factors Bad and Bim, resulting in the release of the pro-survival factors Bcl-2 and Bcl-xL, which migrate into the mitochondrial matrix and inhibit the release of cytochrome C (cyto C), thus inhibiting apoptosis. Akt also phosphorylates the transcription factor FOXO1, promoting its nuclear exclusion and inhibiting FOXO1-mediated transcription of pro-apoptotic factors (6, 39, 40); b) Ras-Raf-MEK1-ERK1 signaling pathway, resulting in the activation of transcription factors associated with cell proliferation (AP-1 and Elk1); c) JAK1-STAT3 signaling pathway, leading to the formation of STAT3 homodimers and their nuclear translocation (6, 39–41). Another recently described mechanism which may account for the activation of genes associated with cell proliferation is the activation of the non-canonical NF-κB signaling pathway by the endosomal C5b-9 complexes, involving the NF-κB-inducing kinase (NIK) (42). An important consequence of C5b-9 assembly is the increased concentration of cytosolic calcium ions (Ca^{2+}), either through direct entry of extracellular Ca^{2+} or by endoplasmic reticulum release triggered by intracellular second messengers (43) (not shown).

From the membrane surface was inhibited by pretreatment with pertussis toxin, suggesting the involvement of a Gi protein (38).

One of the pioneer studies on sublytic C5b-9-induced tumor cell proliferation through mitotic signaling (40) demonstrated that a significant increase in DNA synthesis over the C5b6 level is induced by C5b-9 in the human lymphoblastoid B cell line JY 25. This effect (but not the basal DNA synthesis activity) could be abrogated by pertussis toxin pretreatment, indicating the involvement of activated Gi proteins in DNA synthesis induced by C5b-9 in tumor cells (40) (Figure 1). Pretreatment of cells with PD98059 (specific inhibitor of MEK1 activation) was also effective in abolishing C5b-9-induced DNA synthesis (40). Both ERK1, a member of a potentially pro-oncogenic signal transduction pathway, and PI3K contribute to the transmission of downstream cellular effects prompted by sublytic C5b-9 (40, 46, 47). Indeed, as shown by Pilzer et al., C5b-9 deposition on the K562 leukemic cell membrane activates PKC and ERK protein kinases (48), which then induce the relocation of the mitochondrial chaperone mortalin from the mitochondria to the plasma membrane, where mortalin escorts exo-vesiculated C5b-9 complexes (49). Co-localization of mortalin and C5b-9 in distinct puncta at the leukemic cell plasma membrane region has also been well-documented (49). Mortalin is overexpressed in a multitude of malignancies, and a high level of circulating mortalin was recently demonstrated to correlate with high mortality in colorectal cancer patients (50). Mortalin supports the process of carcinogenesis by suppressing pathway-mediated growth-inhibitory signaling, inactivating tumor suppressor p53, and activating epithelial-to-mesenchymal transition (EMT) signaling (51). In addition, Rozenberg et al. has found that HSP90 binds to mortalin and protects cells from complement-mediated cytotoxicity by inhibiting, together with mortalin, C5b-9 assembly on the plasma membrane (52).

Among the signal transduction networks regulating cancer progression that have been found to function downstream of sublytic C5b-9 are p38/MAPK/JNK1 and JAK1/STAT3 (39, 41).
Cellular proliferation induced by membrane-inserted sublytic C5b-9 relies on the activation of the Gi protein/Pi3K/Akt kinase and Ras/Raf-1/ERK1 pathways and regulation of cell cycle-specific genes and proto-oncogenes (5, 47) (Figure 1).

Of note, activation of activating protein 1 (AP-1) transcription factor has also been documented following C5b-9 treatment of lymphoblastoid B-cell lines (40). Consistent with this finding, stimulation with C5b-9 enhances the expression of the oncogenic proteins c-jun, JunD, and c-fos (53). AP-1 functions are dependent on the specific Fos and Jun subunits contributing to AP-1 dimers (54). AP-1 activity is crucial to oncogenesis, and there is evidence that it has an ambivalent role: while it can act as a tumor promoter in some cancer types, it also represses tumor formation in others (54). NF-κB is another major transcription factor known to be activated by sublytic C5b-9 (42, 47, 55). Sublytic C5b-9–induced, NF-κB–regulated proteins may further enhance cell survival (56) (Figure 1).

In smooth muscle cells (SMC), sublytic assault by MAC stimulates release of insulin-like growth factor-1 (57), whereas in glomerular epithelial cells it causes transactivation of the receptors for epidermal growth factor (EGF), human epidermal growth factor 2/Neu, fibroblast growth factor, and hepatocyte growth factor, all vital growth factors during tumor development (58). CT26 colon carcinoma cells exposed to sublytic C5b-9 exhibit significant changes in genes involved in Ca^{2+} and G-protein signal transduction, early response transcription factors (ERG1, EGR2) and four genes encoding proteins with extracellular localization: AREG, CXC1, MMP3, and MMP13 (59). Network analysis has suggested an important role for the EGF receptor as the main canonical signaling cascade in the response to sublytic C5b-9 in the colon carcinoma cells (59). This connection is very pertinent to carcinogenesis, since alterations in EGF receptor signaling are common events in several human cancers (60).

Non-lethal C5b-9 activates cell cycle by directly influencing major cell cycle regulators: in aortic SMC, sublytic C5b-9 increases the activity of the cyclin-dependent kinases CDK4 and CDK2, whereas in endothelial cells it increases the levels of cell division cycle protein 2 (CDC2), cyclin D1, and proliferating cell nuclear antigen (PCNA) (39).

**SUBLYTIC C5b-9 PROTECTS TUMOR CELLS FROM APOPTOSIS**

Sublytic complement-induced protection against TNF-α–mediated apoptosis accompanies the induction of the anti-apoptotic proteins Bcl-2 and Bcl-xl, along with suppressing the TNF-α–induced decrease in the amount of Bcl-2 and Bcl-xl (61, 62). The anti-apoptotic effects of sublytic C5b-9 encompass events such as activation of NF-κB and inhibition of caspase-8 activation (61, 63, 64). Fascinating insight into the relationship of microvesicles to apoptosis has been provided by the work of Stratton et al. in prostate cancer cells (43). Sublytic C5b-9 deposition is among the positive signals that result in a high Ca^{2+} cellular influx and membrane depolarization; stimulation of microvesicle release then ensures shedding of excess intracellular calcium and export of damaging agents such as deposited C5b-9 and caspase-3. This circuit provides cells with an effective mechanism to thwart apoptosis (43).

It should be noted, however, that data also exist in support of the ability of sublytic C5b-9 to activate various molecules that potentially contribute to programmed cellular death. In lung epithelial cells, MAC insertion has been observed to induce Ca^{2+} influx, leading to mitochondrial overload and loss of mitochondrial transmembrane potential. These changes prompt NLRP3 inflammasome activation, as well as IL-1β production, cytoplasmatic cytochrome c release and caspase activation (65). A similar chain of events has been described in macrophages in which “bystander” deposition of MAC on the plasma membranes of phagocytic macrophages incite NLRP3 inflammasome and caspase-1 activation, together with IL-1β and IL-18 release (66). Bystander C5b-9 deposition has also been found to modulate T-cell polarization and leucocyte recruitment to the phagocytic sites (66). Despite the analogy with apoptosis, the involvement of NLRP3 inflammasomes, caspase-1, IL-1β, and IL-18 rather evokes another form of programmed cellular death, pyroptosis (67). While activation of pyroptosis provides powerful ammunition against many types of cancers, other researchers have reported that the NLRP3 inflammasome and IL-1β pathway promote cancer progression in animal and human breast cancer models (68) and asbestos-induced malignant mesothelioma (69). In addition, sublytic C5b-9 has been shown to interact with effectors of TNFα–induced necroptosis, yet another type of programmed cell death: exposure of human erythroleukemia K562 cells to sublytic C5b-9 causes the activation of RIPK1, RIPK3, and MLKL, co-localization of RIPK3 with RIPK1 in the cytoplasm and co-localization of RIPK3 and MLKL with C5b-9 at the plasma membrane (28). The meaning of the association between C5b-9 and necroptotic effectors has many nuances: RIPK3 and MLKL are in fact seen as putative tumor suppressors (70), but in vitro work in breast cancer cells has recently highlighted the contributions of the necroptotic genes RIPK1, RIPK3, and MLKL in promoting anchorage-independent tumor growth and mediating tumor cell resistance to radiation (71).

**C5b-9 AND ANGIOGENESIS**

Although initiated by cellular destruction and hypoxia, the propagation of the vascular network in a malignant environment is sustained by upregulation of pro-angiogenic factors (e.g. vascular endothelial growth factor [VEGF], TGF-α, TGF-β, TNF-α, EGF, fibroblast growth factor [FGF]) and downregulation of negative angiogenic regulators (II-10, IL-12, angiopoietin-2, angiotensin) (72).

Accelerated C5b-9 deposition, accompanied by VEGF, β-FGF, and TGF-β2 release is seen during laser-induced choroidal neovascularization in age-related macular degeneration in CD59-deficient mice (73). Likewise, exposure of retinal pigment epithelium cells to oxidative stress has been found to induce sublytic C5b-9 activation, triggering VEGF secretion via the Src and Ras-Erk pathways (74).
The effects of C5b-9 were later corroborated in cancer cells. In an osteosarcoma epithelial cell line, sublytic C5b-9 activation (via the alternative pathway) instigated production of angiogenic growth factors FGF1 and VEGF-A via the ERK signaling pathway (12).

RGC-32 AND CANCER

The RGC-32 gene was first cloned from rat oligodendrocytes via differential display by Badea and coworkers, in their quest to identify the genes differentially expressed in response to sublytic complement activation (75, 76). RGC-32 fundamentally regulates cellular processes such as the cell cycle, differentiation, wound healing and tumorigenesis (75, 77). It directly binds to cyclin-dependent kinase CDC2 and Akt and stimulates their kinase activity (75, 78).

Various studies have described an aberrant RGC-32 mRNA expression in human cancers: up-regulation in colon (79, 80), ovarian (81, 82), breast (79, 83, 84) and prostate (79) cancers and lymphomas (85, 86) and downregulation in glioblastomas (87), astrocytomas (88), adenocortical carcinomas (89), and multiple myelomas (90).

We have originally demonstrated a role for RGC-32 deregulation in colon adenocarcinoma, showing that the intensity of RGC-32 immunohistochemical staining corresponded to the increase in the TNM staging of the adenocarcinomas (77). Later, the expression of RGC-32 was shown to be up-regulated in pancreatic cancer tissues and to correlate with TNM stages (91).

Using a gene array and SW480 colon adenocarcinoma cells, we have identified groups of genes that are significantly changed by RGC-32 silencing (77), including genes implicated in chromatin assembly, cell cycle, and RNA processing. We have observed increased lysine acetylation at multiple sites on histones H2B, H3, and H4, and lessened expression of the histone deacetylase SIRT1 upon silencing of RGC-32 expression in SW480 cells (77) (Figure 2). Moreover, an absence of RGC-32 expression induces DNA synthesis and mitosis in colon cancer cells (77). Correspondingly, overexpression of RGC-32 in several cancer cell lines has been shown to delay G2/M cell cycle progression (88).

On the other hand, others have reported that RGC-32 promotes malignant cell proliferation in the colon adenocarcinoma cell line SW480 (80) and in lung adenocarcinoma LTE cells (92). Overexpression of RGC-32 protein in Epstein Barr virus (EBV)-immortalized B cells has been found to disrupt the G2/M checkpoint via CDK1 activation, and RGC-32 has been shown to be indispensable for the growth and survival of lymphoblastoid B cells (86, 93) (Figure 2).

The cooperation of RGC-32 with SMAD3, as TGF-β downstream effectors, in the regulation of EMT seen in renal tubular cells (95) indicates a possible involvement of RGC-32
in invasion and metastasis. RGC-32 was shown to influence expression of vimentin, cadherin, and the transcription factors Snail and Slug in pancreatic and colon cancer lines (80, 91) (Figure 2). Also, excessive RGC-32 expression in a colon cancer cell line prompts cytoskeleton reorganization and cell migration (96). Similarly, RGC-32 has been demonstrated to induce EMT and to promote cancer cell migration and invasion in lung adenocarcinoma cells via decreases in the protein level and activity of the matrix metalloproteinases MMP-2 and MMP-9 (92, 97).

Research focusing on the effects of RGC-32 in animal cancer models has yielded contrasting data. Colon cancer tumors lacking RGC-32 that were implanted into nude mice were observed to have a lower growth rate and significantly smaller tumor volumes than did the tumors with intact RGC-32 expression (80). In striking contrast, inoculating RGC-32 into colon cancer tumors placed subcutaneously in mice resulted in a significant tumor growth suppression and decline in angiogenesis (94) (Figure 2).

The thesis of RGC-32 as a functional dyad (tumor suppressor/promoter) accounts for its contradictory behavior during cancerogenesis: the protein acts in a pleiotropic manner in distinct malignant settings, dependent on the cellular lineage and on the various ligands. For instance, RGC-32 exerts a tumor-suppressive effect in lung adenocarcinomas with wild-type TP53, but a tumor-promoting effect in the tumors carrying TP53 mutations (98). Targeting RGC-32 should be done in conjunction with the role played in specific tumors as well as by using biomarkers that can predict the efficacy of RGC-32 inhibitors in cancer patients.

Future studies are needed in order to find effective RGC-32-based drugs.

CONCLUSIONS

Considering all the available data, the role of C5b-9 in cancer is indisputably versatile: while it is lethal to tumor cells in a lytic context, when C5b-9 becomes activated to a sublytic level, it instead stimulates tumor growth through several mechanisms. Counteracting these tumor-promoting traits of C5b-9 by therapeutically surmounting CDC resistance in cancer cells and potentiating the antitumoral actions of C5b-9 (and therefore the efficacy of mAb-based immunotherapy) constitutes the next major direction in the field of immuno-oncology.

AUTHOR CONTRIBUTIONS

HR designed the study. SV, AT, VR, and HR wrote the manuscript. All authors approved the manuscript.

FUNDING

This work was supported in part by a Veterans Administration Merit Award I01BX001458 (to HR) and by an RO1 NS42011 grant (to HR).

ACKNOWLEDGMENTS

We thank Dr. Deborah McClellan for editing this manuscript.

REFERENCES

1. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. (2011) 144:646–74. doi: 10.1016/j.cell.2011.02.013
2. Balkwill FR, Mantovani A. Cancer-related inflammation: common themes and therapeutic opportunities. Semin Cancer Biol. (2012) 22:33–40. doi: 10.1016/j.semcancer.2011.12.005
3. Niculescu F, Rus HG, Retegan M, Vlaicu R. Persistent complement activation on tumor cells in breast cancer. Am J Pathol. (1992) 140:1039–43.
4. Shin ML, Rus HG, Niculescu FI. Membrane attack by complement: assembly and biology of terminal complement complexes. In: Lee AG, editor. Biomembranes: A Multi-Volume Treatise. Volume 4. JAI Press (1996). p. 123–49.
5. Tegla CA, Cudrici C, Patel S, Trippe R III, Rus V, Niculescu F, et al. Membrane attack by complement: the assembly and biology of terminal complement complexes. Immunol Res. (2011) 51:45–60. doi: 10.1007/s12026-011-8239-5
6. Vlaicu SI, Tegla CA, Cudrici CD, Danoff J, Madani H, Sugarman A, et al. Role of C3b-9 complement complex and response gene to complement-32 (RGC-32) in cancer. Immunol Res. (2013) 56:109–21. doi: 10.1007/s12026-012-8381-8
7. Yamakawa M, Yamada K, Tsuge T, Ohnuki H, Ogata T, Dobashi M, et al. Protection of thyroid cancer cells by complement-regulatory factors. Cell. (1994) 73:2808–17.
8. Cho MS, Vasquez HG, Rupaimooe R, Pradeep S, Wu S, Zand B, et al. Autocrine effects of tumor-derived complement. Cell Rep. (2014) 6:1085–95. doi: 10.1016/j.celrep.2014.02.014
9. Chen J, Yang WJ, Sun HJ, Yang X, Wu YZ. C5b-9 Staining Correlates With Clinical and Tumor Stage in Gastric Adenocarcinoma. Appl Immunohistochem Mol Morphol. (2016) 24:470–5. doi: 10.1097/PAI.0000000000000218
10. Inoue T, Yamakawa M, Takahashi T. Expression of complement regulating factors in gastric cancer cells. Mol Pathol. (2002) 55:193–9. doi: 10.1136/mp.55.3.193
11. Niehans GA, Cherwitz DL, Staley NA, Knapp DJ, Dalmasse AP. Human carcinomas variably express the complement inhibitory proteins CD46 (membrane cofactor protein), CD55 (decay-accelerating factor), and CD59 (protectin). Am J Pathol. (1996) 149:129–42.
12. Jeon H, Han SR, Lee S, Park SJ, Kim JH, Yoo SM, et al. Activation of the complement system in an osteosarcoma cell line promotes angiogenesis through enhanced production of growth factors. Sci Rep. (2018) 8:5415. doi: 10.1038/s41598-018-23851-z
13. Bouwens TA, Trouw LA, Veerhuis R, Dirven CM, Lamfers ML, Al-Khawaja H. Complement activation in Glioblastoma multiforme pathophysiology: evidence from serum levels and presence of complement activation products in tumor tissue. J Neuroimmunol. (2015) 278:271–6. doi: 10.1016/j.jneuroim.2014.11.016
14. Bjorge L, Hakulin J, Vintermyr OK, Jarve H, Jensen TS, Iversen OE, et al. Asctic complement system in ovarian cancer. Br J Cancer. (2005) 92:895–905. doi: 10.1038/sj.bjc.6602334
15. Murakoshi Y, Honda K, Sasazuki S, Ono M, Negishi A, Matsubara J, et al. Plasma biomarker discovery and validation for colorectal cancer by quantitative shotgun mass spectrometry and protein microarray. Cancer Sci. (2011) 102:630–8. doi: 10.1111/j.1349-7006.2010.01818.x
16. Chong PK, Lee H, Loh MC, Choong LY, Lin Q, So JB, et al. Upregulation of plasma C9 protein in gastric cancer patients. Proteomics. (2010) 10:3210–21. doi: 10.1002/pmic.201000127
17. Gallenkamp J, Spanier G, Worle E, Engbrecht M, Kirschfink M, Greslechner R, et al. A novel multiplex detection array revealed systemic complement activation in oral squamous cell carcinoma. *OncoTarget*. (2018) 9:5001–13. doi: 10.18632/oncotarget.22963

18. Narayanasamy A, Ahn JM, Sung HJ, Kong DH, Ha KS, Lee SY, et al. Fucosylated glycoproteins: a promising approach to identify a complement component 9 associated with squamous cell lung cancer (SCLC). *J Proteomics*. (2011) 74:2948–58. doi: 10.1016/j.jprot.2011.07.019

19. Macor P, Capolla S, Tedesco F. Complement as a biological tool to control tumor growth. *Front Immunol*. (2018) 9:2203. doi: 10.3389/fimmu.2018.02203

20. Taylor RP, Lindorfer MA, Trump BF, Shin ML. Complement-mediated cell death displays multi-hit characteristics. *Proc Natl Acad Sci USA*. (1983). 80:3816–20.

21. Reis ES, Mastellos DC, Ricklin D, Mantovani A, Lambris JD. Complement. *Nat Rev Immunol*. (2013) 13:1804–9.

22. Papadimitriou JC, Drachenberg CB, Shin ML, Trump BF. Activation of Ras and mitogen-activated protein kinase pathway by terminal complement complex is G protein dependent. *J Immunol*. (1997) 158:4405–12.

23. Papadimitriou JC, Ramm LE, Drachenberg CB, Shin ML, Trump BF. Ultrastructural studies of complement mediated cell death: a biological reaction model to plasma membrane injury. *Virchows Arch*. (1994) 424:677–85.

24. Coggins MS, Howitt WJ, Bloodworth L, Anderson VA, Morgan BP, Glennie MJ. Complement-mediated cell death is associated with DNA fragmentation. *Cell Death Differ*. (2000) 7:48–58. doi: 10.1038/sj.cdd.4400627

25. Ganz C, Fishelson Z. Cancer resistance to complement-dependent cytotoxicity (CDC): Problem-oriented research and development. *Mol Immunol*. (2009) 46:2794–800. doi: 10.1016/j.molimm.2009.05.009

26. Ziporen L, Donin N, Shmushkovich T, Gross A, Fishelson Z. Programmed necrotic cell death induced by complement involves a Bid-dependent pathway. *J Immunol*. (2009) 182:515–21. doi: 10.4049/jimmunol.182.1.515

27. Declereudt C, Ricklin D, Mantovani A, Lambris JD. Cooperation between Hsp90 and mortalin/GRP75 in resistance to cell death mediated by C5b-9. *J Immunol*. (1991) 147:212–7.

28. Zindy O, Ziporen L, Donin N, Fishelson Z. Membrane complement regulators improve complement-dependent cytotoxicity by microRNAs miR-200b, miR-200c, and miR-217. *J Immunol*. (2016) 196:5156–65. doi: 10.4049/jimmunol.1502701

29. Rus HG, Niculescu FI, Shin ML. Role of the C5b-9 terminal complement complex in cell cycle and apoptosis. *Immunol Rev*. (2001) 180:49–55. doi: 10.1034/j.1600-065x.2001.1800101.x

30. Niculescu F, Rus H, Shin ML. Receptor-independent activation of guanine nucleotide-binding regulatory proteins by terminal complement complexes. *J Biol Chem*. (1994) 269:4147–23.

31. Fosbrink M, Niculescu F, Rus H. The role of C5b-9 terminal complement complex in activation of the cell cycle and transcription. *Immunol Res*. (2005) 31:37–46. doi: 10.1385/IR:31:1:37

32. Niculescu F, Rus H, van Biesen T, Shin ML. Activation of Ras and mitogen-activated protein kinase pathway by terminal complement complexes is G protein dependent. *J Immunol*. (1997) 158:4405–12.

33. Niculescu F, Sozne L, Badea T, Shin M, Rus H. Tyrosine phosphorylation and activation of Janus kinase 1 and STAT3 by sublytic C5b-9 complement complex in aortic endothelial cells. *Immunopharmacology*. (1999) 42:187–93. doi: 10.1016/S0161-5890(03)00112-3

34. Jane-wit D, Surovtseva YV, Qin L, Li G, Liu R, Clark P, et al. Complement membrane attack complexes activate noncanonical NF-kappaB by forming an Akt+-NIK+-signalingosome on Rab5+-endosomes. *Proc Natl Acad Sci USA*. (2011) 108:9686–91. doi: 10.1073/pnas.1015355112

35. Stratton D, Moore C, Antiwi-Balfour S, Lange S, Inal J. Microwebsicles released constitutively from prostate cancer cells differ biochemically and functionally to stimulated microwebsicles released through sublytic C5b-9. *Biochem Biophys Res Commun*. (2015) 460:589–95. doi: 10.1016/j.bbrc.2015.03.074

36. Carney DF, Lang TJ, Shin ML. Multiple signal messengers generated by terminal complement complexes and their role in terminal complement complex elimination. *J Immunol*. (1990) 145:623–9.

37. Niculescu F, Rus H, Shin S, Lang T, Shin ML. Generation of diacylglycerol and ceramide during homologous complement activation. *J Immunol*. (1993) 150:214–21.

38. Badea T, Rus H, Shin ML. Complex C5b-9 induces proliferation of human aortic smooth muscle cells: role of mitogen activated protein kinase and phosphatidylinositol 3-kinase. *Atherosclerosis*. (1999) 142:47–56. doi: 10.1016/S0021-9150(98)00185-3

39. Niculescu F, Rus H. Mechanisms of signal transduction activated by sublytic assembly of terminal complement complexes on nucleated cells. *Immunol Res*. (2001) 24:191–9. doi: 10.1385/IR:24:2:191

40. Pilzer D, Fishelson Z. Mortalin/GRP75 promotes release of membrane vesicles from immune attacked cells and protection from complement-mediated lysis. *Int Immunol*. (2005) 17:1239–48. doi: 10.1093/intimm/dih300

41. Makwerthe N, Rocca F, Schwert JR, Geisler C, Hillman Y, Egner A, et al. Complement triggers relocation of Mortalin/GRP75 from mitochondria to the plasma membrane. *Immunobiology*. (2016) 221:1395–406. doi: 10.1016/j.imbio.2016.07.005

42. Rubran R, Kocsis J, Garam N, Malati E, Gombos T, Barabas L, et al. Circulating mitochondrial stress 70 protein/mortalin and cytosolic Hsp70 in blood: risk indicators in colorectal cancer. *Int J Cancer*. (2017) 141:2239–35. doi: 10.1002/ijc.30918

43. Yun CO, Bhargava P, Na Y, Lee JS, Ryu J, Kaul SC, et al. Relevance of mortalin to cancer cell stemness and cancer therapy. *Sci Rep*. (2017) 7:42016. doi: 10.1038/srep42016

44. Rozenberg P, Ziporen L, Ganz C, Saar-Ray M, Fishelson Z. Cooperation between Hsp90 and mortalin/GRP75 in resistance to cell death induced by complement C5b-9. *Cell Death Dis*. (2018) 9:150. doi: 10.1038/s41419-017-0240-z

45. Viedt CD, Hensch GM, Brandes RP, Kubler W, Kreuzer J. The terminal complement complex C5b-9 stimulates interleukin-6 production in human smooth muscle cells through activation of transcription factors NF-kappa B and AP-1. *Faseb J*. (2000) 14:2370–2. doi: 10.1096/fj.00-0468fje
56. Ganze D, Lusthaus M, Fishelson Z. A role for the NF-kappaB pathway in cell protection from complement-dependent cytotoxicity. J Immunol. (2012) 189:860–6. doi: 10.4049/jimmunol.1103451

57. Zwaka TP, Torzewski J, Hoeflich A, Dejosez M, Kaiser S, Hombach V, et al. The terminal complement complex inhibits apoptosis in vascular smooth muscle cells by activating an autocrine IFN-1 loop. Faseb J. (2003) 17:1346–8. doi: 10.1096/fj.02-80145fe

58. Cybulsky AV, Takano T, Papillon J, McTavish AJ. Complement C5b-9 induces receptor tyrosine kinase transactivation in glomerular epithelial cells. Am J Pathol. (1999) 155:1701–11. doi: 10.1016/S0002-9440(10)65485-5

59. Towner LD, Wheat RA, Hughes TR, Morgan BP. Complement membrane attack and tumorigenesis: a systems biology approach. J Biol Chem. (2016) 291:14927–38. doi: 10.1074/jbc.M115.708446

60. Sigismund S, Avanzato D, Lanzetti L. Emerging functions of the EGFR in cancer. Mol Oncol. (2018) 12:3–20. doi: 10.1016/j.molonc.2017.12.005

61. Liu L, Li W, Li Z, Kirschfink M. Sublytic complement protects prostate cancer cells from tumour necrosis factor-alpha-induced cell death. Clin Exp Immunol. (2012) 169:100–8. doi: 10.1111/j.1365-2249.2012.0596.x

62. Soane L, Rus H, Niculescu F, Shin ML. Inhibition of oligodendrocyte apoptosis by sublytic C5b-9 is associated with enhanced synthesis of bcl-2 and mediated by inhibition of caspase-3 activation. J Immunol. (1999) 163:6132–8.

63. Cudrici C, Niculescu F, Jensen T, Zafranskaia E, Fosbrink M, Rus V, et al. C5b-9 terminal complex protects oligodendrocytes from apoptotic cell death by inhibiting caspase-8 processing and up-regulating FLIP. J Immunol. (2006) 176:1373–80. doi: 10.4049/jimmunol.176.5.1373

64. Soane L, Cho HJ, Niculescu F, Rus H, Shin ML. C5b-9 terminal complement complex protects oligodendrocytes from death by regulating Rad through phosphatidylinositol 3-kinase/Akt pathway. J Immunol. (2001) 167:2305–11. doi: 10.4049/jimmunol.167.4.2305

65. Triantafilou K, Hughes TR, Triantafilou M, Morgan BP. The complement membrane attack complex triggers intracellular Ca2+ fluxes leading to NLRP3 inflammasome activation. J Cell Sci. (2013) 126:2903–14. doi: 10.1242/jcs.124388

66. Suresh R, Chandrasekaran P, Sutterwala FS, Mosser DM. Complement-mediated bystander damage initiates host NLRP3 inflammasome activation. J Cell Sci. (2016) 129:1928–39. doi: 10.1242/jcs.179291

67. Kolb JP, Ogün TH III, Oberst A, Martinez J. Programmed cell death and inflammation: winter is coming. Trends Immunol. (2017) 38:705–18. doi: 10.1016/j.tit.2017.06.009

68. Guo B, Fu S, Zhang J, Liu B, Li Z. Targeting inflammasomes/IL-1 pathways for cancer immunotherapy. Sci Rep. (2016) 6:36107. doi: 10.1038/srep36107

69. Kadaraya Y, Menges CW, Talarchek J, Cai QK, Klein-Szanto AJ, Pietrofesa NR, et al. Inflammation-Related IL-1beta/IL1R Signaling Promotes the Development of Asbestos-Induced Malignant Mesothelioma. Cancer Prev Res. (2016) 9:406–14. doi: 10.1158/1940-6207.CPR-15-0347

70. Krysko O, Aaes TL, Kagan VE, D’Herde K, Bachert C, Leybaert L, et al. Investigating the role of RGC-32, a novel gene induced by complement and characterized of RGC-32, a novel gene induced by complement activation in oligodendrocytes. J Biol Chem. (1998) 273:26977–81. doi: 10.1074/jbc.273.41.26977

71. Vlaiuc SI, Tegla CA, Cudrici CD, Fosbrink M, Nguyen V, Azimzadeh P, et al. Epigenetic modifications induced by RGC-32 in colon cancer. Exp Mol Pathol. (2010) 88:67–76. doi: 10.1016/j.yexmp.2009.10.010

72. Fosbrink M, Cudrici C, Tegla CA, Soloviova I, Ito T, Vlaiuc SI, et al. Response gene to complement 32 is required for C5b-9 induced cell cycle activation in endothelial cells. Exp Mol Pathol. (2009) 86:87–94. doi: 10.1016/j.yexmp.2008.12.005

73. Fosbrink M, Cudrici C, Niculescu F, Badea TC, David S, Shamsuddin A, et al. Overexpression of RGC-32 in colon cancer and other tumors. Exp Mol Pathol. (2005) 78:116–22. doi: 10.1016/j.yexmp.2004.11.001

74. Wang XY, Li SN, Zhu HF, Hu ZY, Zhong Y, Gu CS, et al. RGC32 induces epithelial-mesenchymal transition by activating the Smad/Sip1 signaling pathway in CRC. Sci Rep. (2017) 7:60678. doi: 10.1038/srep60678

75. Cho H, Lim BJ, Kang ES, Choi JS, Kim JH. Molecular characterization of a new ovarian cancer cell line, YDVO-151, established from mucinous cystadenocarcinoma. Tohoku J Exp Med. (2009) 218:129–39. doi: 10.1620/tim.218.129

76. Donninger H, Bonome T, Radonovich M, Pise-Masison CA, Brady J, Shih JH, et al. Whole genome expression profiling of advance stage papillary serous ovarian cancer reveals activated pathways. Oncogene. (2004) 23:8065–77. doi: 10.1038/sj/onc.1207959

77. Eskandari-Nasab E, Hashemi M, Rafiegdoost F. Promoter Methylation and mRNA expression of response gene to complement 32 in breast cancer. Cancer Epidemiol. (2016) 2016:7680523. doi: 10.1159/2016.7680523

78. Kang Y, Siegel PM, Shu W, Drobnjak M, Kakonen SM, Cardo-Cardo C, et al. A multigenic program mediating breast cancer metastasis to bone. Cancer cell. (2003) 5:357–49. doi: 10.1016/S1535-6108(03)01132-6

79. Hahn A. Differenzielle Genexpression der Gene APR-1, B56, RGC32 und SIAT-8A bei kutanen T-Zell-Lymphomen. Dissertation, Heidelberg: Ruprecht-Karls-Universität Heidelberg Fakultät für Klinische Medizin Mannheim, (2006).

80. Schlick S. Investigating the role of RGC-32 in cell cycle disruption by EBV ERNA.3C. Dissertation, Sussex: School of Life Sciences, University of Sussex, (2010).

81. Bredel M, Bredel C, Juric D, Duran GE, Yu RX, Harsh GR, et al. Tumor necrosis factor-alpha-induced protein 3 as a putative regulator of nuclear factor-kappab-mediated resistance to O6-alkylating agents in human glioblastomas. J Clin Oncol. (2006) 24:274–87. doi: 10.1200/JCO.2005.02.9405

82. Saigusa K, Imoto I, Tanikawa C, Aoyagi M, Ohno K, Nakamura Y, et al. RGC32, a novel p53-inducible gene, is located on centrosomes during mitosis and results in G2/M arrest. Oncogene. (2007) 26:1110–21. doi: 10.1038/sj.onc.1210148

83. Demeure MJ, Coan KE, Grant CS, Komorowski RA, Stephan E, Sinari S, et al. PTIT1 overexpression in adenocarcinical cancer is associated with poor survival and represents a potential therapeutic target. Surgery. (2013) 154:105–16; discussion 16. doi: 10.1016/j.surg.2013.06.058

84. Zhan F, Huang Y, Colla S, Stewart JP, Hanamura I, Gupta S, et al. The molecular classification of multiple myeloma. Blood. (2006) 108:2020–8. doi: 10.1182/blood-2005-11-13458

85. Zhu L, Qin H, Li PY, Xu SN, Pang HF, Zhao HZ, et al. Response gene to complement 32 increases p34CDC2 kinase activity and entry of aortic smooth muscle cells into S-phase. J Biol Chem. (2002) 277:502–8. doi: 10.1074/jbc.M109354200

86. Badea TC, Niculescu FI, Soane L, Shin ML, Rus H. Molecular cloning and characterization of RGC-32, a novel gene induced by complement activation in oligodendrocytes. J Biol Chem. (1998) 273:26977–81. doi: 10.1074/jbc.273.41.26977
96. Tian J, Xu C, Yang MH, Li ZG. [Overexpression of response gene to complement-32 promotes cytoskeleton reorganization in SW480 cell line]. *Nan Fang Yi Ke Da Xue Xue Bao*. (2011) 31:1179–82.

97. Sun Q, Yao X, Ning Y, Zhang W, Zhou G, Dong Y. Overexpression of response gene to complement 32 (RGC32) promotes cell invasion and induces epithelial-mesenchymal transition in lung cancer cells via the NF-kappaB signaling pathway. *Tumour Biol.* (2013) 34:2995–3002. doi: 10.1007/s13277-013-0864-2

98. Kim DS, Lee JY, Lee SM, Choi JE, Cho S, Park JY. Promoter methylation of the RGC32 gene in nonsmall cell lung cancer. *Cancer*. (2011) 117:590–6. doi: 10.1002/cncr.25451

**Conflict of Interest Statement:** The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Copyright © 2019 Vlaicu, Tatomir, Rus and Rus. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.